Search BioPortfolio:
BioPortfolio
Web
Home
Marketing Services
News
Reports
Company Profiles
InDepth
Drug Discovery
Careers
Conferences
Videos
Search
Contact
Items Ordered:
Cart Value:
New Products:
1.
Investigator-Initiated Trials: Building Superior IIT Capabilities (PH114)
2.
A Guidebook to Pharma Brand Optimization: Lifecycle Management Strategy (PH108)
3.
Sleep Disorders Market Analysis 2008-2018
4.
Biogenerics, World Market
5.
The Return of the Rx to OTC Switch Market Analysis and Product Management Strategies
6.
The Vaccines 2008 World Market Analysis, Key Players, and Critical Trends in a Fast-Changing Industry
7.
Key Topics in Pharmaceutical Market Strategy 2008 (Drug Pricing, Rx to OTC switches, Retail Clinics, Prescribing Pharmacists, The Growing Out of Pocket Healthcare Market)
8.
INFLAMMATORY DIRECTIONS Strategies for Six Diseases with Unmet Needs
9.
Cardiac Toxicity
10.
Biopharm Outsourcing Register
Best Sellers:
1.
Good Laboratory Practice (GLP) course
2.
BioNewsCast Press Release Distribution Service
3.
The World Contract Research and Manufacturing Market, 2006-2011 - Trends in Outsourcing
4.
Antibiotics and Drug Resistance 2007
5.
Biopharm Outsourcing Register
6.
Life Sciences Mergers & Acquisitions (M&A)
7.
Transdermal Drug Delivery - Technologies, Markets, and Companies
8.
The Future of Targeted Therapeutics Key technologies, new therapy area applications and leading players
9.
Heart Health Food and Drinks NPD in cardiovascular health, hypertension and cholesterol reduction
10.
The World Allergy Market 2006-2011 - The Rx-OTC Rush
High-Content Screening (HCS): An Industry Analysis
by Enal S. Razvi, Ph.D.
Published: March, 2006
220+ Pages - 24 Exhibits - 24 Companies Profiled
High-content Screening (HCS) is a focused term referring to the re-screening process-referred to sometimes as secondary screening-whereby the use of different types of assays enables a number of different parameters of a system to be assessed, in the presence of given lead compounds (in this manner, the effect of lead compounds on the biological system can be studied and those leads that display significant toxicity, for instance, can be eliminated early in the process-thereby enabling triage of the sub-optimal leads). This is the process of hit to lead triage and is a major segment of the HCS marketplace. In the present context, HCS refers to ensembles of measurements on cells and tissues, which taken together, enable a "more complete picture" of the lead compound, and therefore enables a more calculated approach to triage.
Overview
D&MD's High-Content Screening (HCS) and Analysis report is focused on an emerging and key segment of the life science tools and technology space-high content biology. High content biology has various ramifications in life science research, academic research, drug discovery, and development and in this report we focus on this emerging space, some of the major technologies and products in this space, and the market landscape through both a qualitative and quantitative analysis.
This report focuses on high-content and secondary screening. These disciplines are an outgrowth of high-throughput screening that commanded much attention and resources in the pharmaceutical and biotechnology companies over the past decade. Currently, the challenge has moved towards analyses of sub-cellular organization, morphology, and these are facets of HCS.
In addition to describing the technical aspects of high-content screening (HCS) in this report, we present a thorough market analysis complemented by primary data from a proprietary survey conducted on this topic by D&MD.
Questions Answered
> What are the strategic market opportunities for the high-content analysis/screening space?
> What is the growth rate of the High-Content Screening and Analysis market?
> What are the challenges and bottlenecks in the HCS space?
> Who are the key players in the HCS marketplace?
> What are the major products and technologies available in the HCS marketplace?
Table of Contents
Price
PDF $4,950.00
Printed $4,950.00
CD-ROM $4,950.00
Single Site Licence $6,930.00
Global Site Licence $7,425.00
Buy Biotechnology Management Reports online with BioPortfolio's secure E-Commerce portal.